Nectar lifesciences Limited announced its Q3FY26 financial results for the quarter ended December 31, 2025, showcasing a remarkable turnaround in profitability driven by strategic business divestments. The pharmaceutical company reported a total profit of ₹1,426.97 lacs for the quarter, marking a significant improvement from ₹784.04 lacs in the corresponding quarter of the previous year.

Financial Performance Overview

The company's financial performance for Q3FY26 demonstrates the impact of major business restructuring activities. Total income for the quarter stood at ₹66.08 lacs, comprising entirely of other income, as the company reported no revenue from operations during the period.

Major Business Divestment

The standout feature of the quarter was the completion of significant business transfers that generated substantial exceptional gains. The company successfully completed the sale of its pharmaceutical businesses to Ceph Lifesciences Private Limited through a slump sale arrangement.

The pharmaceutical business transfer included Active Pharmaceutical Ingredients business located at Unit 1 and Unit 2 in Derabassi, Punjab, and Formulation business at Unit 6 in Baddi, Himachal Pradesh. The transaction was completed on November 10, 2025, following shareholder approval on August 4, 2025.

Discontinued Operations Impact

The company's results reflect the classification of divested businesses as discontinued operations in accordance with Indian Accounting Standards. The discontinued operations, which included pharma businesses, menthol assets, and capsule business, showed varied performance across different periods.

Additional Strategic Transactions

Beyond the main pharmaceutical business sale, the company completed two additional asset transfers. The menthol business assets were sold to CEPH for ₹2,000.00 lacs, with full consideration received by December 31, 2025. Additionally, on December 20, 2025, the company entered into an agreement to sell its Empty Hard Gelatin Capsule business to Capnest Health Care Private Limited for ₹1,990.00 lacs, subject to regulatory approvals.

Earnings Per Share Analysis

The company's earnings per share metrics reflect the complex nature of its business restructuring:

Corporate Governance and Approvals

The Board of Directors reviewed and approved these financial results in their meeting held on January 23, 2026, which commenced at 3:00 PM IST and concluded at 4:30 PM IST. The Audit Committee had previously reviewed the results on the same date. Deepak Jindal & Co., Chartered Accountants, conducted the statutory limited review of both standalone and consolidated financial results.

The company also announced a share buyback program approved on December 3, 2025, involving the purchase of 3,00,00,000 equity shares at ₹27.00 per share for an aggregate amount of ₹8,100.00 lacs. The buyback payment was completed on January 13, 2026, with share extinguishment occurring on January 20, 2026.

Source:

Nectar lifesciences Limited has successfully completed the extinguishment of 3,00,00,000 equity shares through its tender offer buyback program. The pharmaceutical company announced the completion of this corporate action on January 21, 2026, following the buyback process that concluded earlier this month.

Buyback Program Details

The tender offer buyback was conducted from December 31, 2025, to January 6, 2026, through the stock exchange mechanism. The company repurchased shares at ₹27.00 per equity share, representing a total buyback value of ₹81.00 crores for the 3 crore shares acquired.

Share Capital Reconciliation

The extinguishment process has resulted in a significant reduction in the company's share capital structure. The buyback was executed in compliance with Regulation 24(iv) read with Regulation 11 of the Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018.

Extinguishment Process

All 3,00,00,000 equity shares were extinguished in dematerialized form through National Securities Depository Limited (NSDL). The shares were processed through Master Capital Services Ltd. (DP ID: IN301143) on January 20, 2026. No equity shares were tendered or extinguished in physical form during this buyback program.

The extinguishment was certified by multiple parties including the company's management, secretarial auditor P. Chadha & Associates, and registrar KFin Technologies Limited. NSDL confirmed the debit of 30,000,000 shares from the depository system on January 20, 2026.

Regulatory Compliance

The buyback program was initiated following the public announcement dated December 4, 2025, published on December 5, 2025, along with a corrigendum published on December 10, 2025. The letter of offer was issued on December 29, 2025, providing shareholders with the necessary details for participation in the tender offer.

The entire process was conducted in accordance with SEBI (Buyback of Securities) Regulations, 2018, and SEBI (Depository and Participants) Regulations, 2018. The company has submitted all required documentation and confirmations to both NSE (Symbol: NECLIFE) and BSE (Scrip Code: 532649) as part of its regulatory obligations.